1 April 2019 in Gastroenterology
1 March 2020 in Journal of Hepatology
11 September 2017 in Hepatology Communications
Cholestatic drug‐induced liver injury (DILI) can be a diagnostic challenge due to a large differential diagnosis, variability in clinical presentation, and lack of serologic biomarkers associated with this condition. The clinical presentation of drug‐induced cholestasis includes bland cholestasis, cholestatic hepatitis, secondary sclerosing cholangitis, and vanishing bile duct syndrome. The associate mortality of cholestatic DILI can be as high as 10%, and thus prompt recognition and removal of the offending agent is of critical importance. Several risk factors have been identified for drug‐induced cholestasis, including older age, genetic determinants, and properties of certain medications. Antibiotics, particularly amoxicillin/clavulanate, remain the predominant cause of cholestatic DILI, although a variety of other medications associated with this condition have been identified. In this review, we summarize the presentation, clinical approach, risk factors, implicated medications, and management of drug‐induced cholestatic liver injury. (Hepatology Communications 2017;1:726–735)
25 March 2019 in Hepatology
Patients listed for liver transplantation (LT) as status 1a currently receive the highest priority on the waiting list. The presence of acute on chronic liver failure (ACLF) with three or more organs failing (ACLF‐3) portends low survival without transplantation, which may not be reflected by the Model for End‐Stage Liver Disease‐Sodium (MELD‐Na) score. We compared short‐term waitlist mortality for patients listed status 1a and those with ACLF‐3 at listing. Data were analyzed from the United Network for Organ Sharing database, years 2002‐2014, for 3,377 patients listed status 1a and 5,099 patients with ACLF‐3. Candidates with ACLF were identified based on the European Association for the Study of the Liver Chronic Liver Failure Consortium criteria. MELD‐Na score was treated as a categorical variable of scores 40. We used competing risks regression to assess waitlist mortality risk. Evaluation of outcomes through 21 days after listing demonstrated a rising trend in mortality among ACLF‐3 patients at 7 days (18.0%), 14 days (27.7%), and 21 days (32.7%) (P < 0.001) compared to a stable trend in mortality among individuals listed as status 1a at 7 days (17.9%), 14 days (19.3%), and 21 days (19.8%) (P = 0.709). Multivariable modeling with adjustment for MELD‐Na category revealed that patients with ACLF‐3 had significantly greater mortality (subhazard ratio, 1.45; 95% confidence interval, 1.31‐1.61) within 14 days of listing compared to status‐1a candidates. Analysis of the interaction between MELD‐Na category and ACLF‐3 showed that patients with ACLF‐3 had greater risk of 14‐day mortality than status‐1a‐listed patients, across all three MELD‐Na categories. Conclusion: Patients with ACLF‐3 at the time of listing have greater 14‐day mortality than those listed as status 1a, independent of MELD‐Na score; these findings illustrate the importance of early transplant evaluation and consideration of transplant priority for patients with ACLF‐3.
12 June 2020 in American Journal of Transplantation
Background Medical‐refractory severe alcoholic hepatitis (AH) has a high mortality. The national frequency, longer‐term outcomes and regional practices of AH liver transplantation (LT) in the US are not well described, despite the increasing mortality from alcohol‐associated liver disease. Methods We analyzed the trends in frequency and outcomes of UNOS data on 39,455 adult patients who underwent LT from 2014‐2019, including AH LT recipients. Results LTs for AH increased 5‐fold, from 28 in 2014 to 138 in 2019, varying 8‐fold between UNOS regions. Three transplant centers accounted for 50‐90% of AH LTs within each region. The number of transplant centers performing AH LTs increased from 14 in 2014 to 47 in 2019. AH patients were younger (mean=39.4 years), had higher MELD scores (mean=36.8), and were more often on dialysis (46.0%) and in ICU (38.4%), compared to other indications (all p values <0.05). One‐ and 5‐year graft survivals for AH LT recipients were 91.7% and 81.9, respectively. Conclusions The frequency of AH LT is increasing rapidly, with excellent medium‐term outcomes. An impact of AH recurrence on patient or graft survival is not apparent in this national analysis. There are marked geographic variations in practices, highlighting the lack of selection criteria standardization.
26 March 2021 in Hepatology Communications
Hepcidin, a peptide hormone produced by hepatocytes, is the central regulator of systemic iron homeostasis through its interaction with ferroportin, the major cellular iron export protein. Hepcidin binding to ferroportin results in reduced iron export from macrophages and intestinal absorptive cells, leading to decreased serum iron levels. Hepcidin expression is influenced by several factors that include serum and liver iron stores, erythropoiesis, hypoxia, inflammation, and infection. Erythropoietic drive and hypoxia suppress hepcidin expression and promote red cell production. In contrast, inflammation and infection are associated with increased hepcidin production to sequester iron intracellularly as a means of depriving microorganisms of iron. Chronic inflammation may up-regulate hepcidin expression through the interleukin-6 (IL-6)–Janus kinase 2 (JAK2)–signal transducer and activator of transcription 3 (STAT3) pathway. The bone morphogenetic protein (BMP)–mothers against decapentaplegic homolog (SMAD) pathway is a major positive driver of hepcidin expression in response to either increased circulating iron in the form of transferrin or iron loading in organs. Hereditary hemochromatosis (HH) consists of several inherited disorders that cause inappropriately reduced hepcidin expression in response to body iron stores, leading to increased iron absorption from a normal diet. The most common form of HH is due to a mutation in the HFE gene, which causes a failure in the hepatocyte iron–sensing mechanism, leading to reduced hepcidin expression; the clinical manifestations of HFE-HH include increased serum transferrin–iron saturation and progressive iron loading in the liver and other tissues over time among patients who express the disease phenotype. In this article, we review the physiologic mechanisms and cellular pathways by which hepcidin expression is regulated, and the different forms of HH resulting from various mutations that cause hepcidin deficiency. We also review other drivers of hepcidin expression and the associated pathophysiologic consequences.